Literature DB >> 27638620

AMPKα2 Regulates Bladder Cancer Growth through SKP2-Mediated Degradation of p27.

Stavros Kopsiaftis1,2, Katie L Sullivan1,2, Isha Garg1,2, John A Taylor3, Kevin P Claffey4,2,5.   

Abstract

AMP-activated protein kinase (AMPK) is the central metabolic regulator of the cell and controls energy consumption based upon nutrient availability. Due to its role in energy regulation, AMPK has been implicated as a barrier for cancer progression and is suppressed in multiple cancers. To examine whether AMPK regulates bladder cancer cell growth, HTB2 and HT1376 bladder cells were treated with an AMPK activator, 5-aminoimidazole-4-carboxamide ribonucleotide (AICAR). AICAR treatment reduced proliferation and induced the expression of p27Kip1 (CDKN1B), which was mediated through an mTOR-dependent mechanism. Interestingly, AMPKα2 knockdown resulted in reduced p27 levels, whereas AMPKα1 suppression did not. To further determine the exact mechanism by which AMPKa2 regulates p27, HTB2 and HT1376 cells were transduced with an shRNA targeting AMPKα2. Stable knockdown of AMPKα2 resulted in increased proliferation and decreased p27 protein. The reduced p27 protein was determined to be dependent upon SKP2. Additionally, loss of AMPKα2 in a xenograft and a chemical carcinogen model of bladder cancer resulted in larger tumors with less p27 protein and high SKP2 levels. Consistent with the regulation observed in the bladder cancer model systems, a comprehensive survey of human primary bladder cancer clinical specimens revealed low levels of AMPKα2 and p27 and high levels of SKP2. IMPLICATIONS: These results highlight the contribution of AMPKα2 as a mechanism for controlling bladder cancer growth by regulating proliferation through mTOR suppression and induction of p27 protein levels, thus indicating how AMPKα2 loss may contribute to tumorigenesis. Mol Cancer Res; 14(12); 1182-94. ©2016 AACR. ©2016 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27638620      PMCID: PMC5136331          DOI: 10.1158/1541-7786.MCR-16-0111

Source DB:  PubMed          Journal:  Mol Cancer Res        ISSN: 1541-7786            Impact factor:   5.852


  49 in total

Review 1.  Post-translational regulation of the tumor suppressor p27(KIP1).

Authors:  J Vervoorts; B Lüscher
Journal:  Cell Mol Life Sci       Date:  2008-10       Impact factor: 9.261

2.  Resveratrol inhibits oesophageal adenocarcinoma cell proliferation via AMP-activated protein kinase signaling.

Authors:  Guang-Hua Fan; Zhong-Ming Wang; Xi Yang; Li-Ping Xu; Qin Qin; Chi Zhang; Jian-Xin Ma; Hong-Yan Cheng; Xin-Chen Sun
Journal:  Asian Pac J Cancer Prev       Date:  2014

3.  AMPKα2 deletion exacerbates neointima formation by upregulating Skp2 in vascular smooth muscle cells.

Authors:  Ping Song; Shuangxi Wang; Chaoyong He; Shaobin Wang; Bin Liang; Benoit Viollet; Ming-Hui Zou
Journal:  Circ Res       Date:  2011-10-06       Impact factor: 17.367

4.  Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells.

Authors:  Mahvash Zakikhani; Ryan Dowling; I George Fantus; Nahum Sonenberg; Michael Pollak
Journal:  Cancer Res       Date:  2006-10-23       Impact factor: 12.701

5.  AMPKα modulation in cancer progression: multilayer integrative analysis of the whole transcriptome in Asian gastric cancer.

Authors:  Yon Hui Kim; Han Liang; Xiuping Liu; Ju-Seog Lee; Jae Yong Cho; Jae-Ho Cheong; Hoguen Kim; Min Li; Thomas J Downey; Matthew D Dyer; Yongming Sun; Jingtao Sun; Ellen M Beasley; Hyun Cheol Chung; Sung Hoon Noh; John N Weinstein; Chang-Gong Liu; Garth Powis
Journal:  Cancer Res       Date:  2012-03-20       Impact factor: 12.701

Review 6.  When urothelial differentiation pathways go wrong: implications for bladder cancer development and progression.

Authors:  David J DeGraff; Justin M Cates; Joshua R Mauney; Peter E Clark; Robert J Matusik; Rosalyn M Adam
Journal:  Urol Oncol       Date:  2011-09-15       Impact factor: 3.498

7.  AMPKα2 Suppresses Murine Embryonic Fibroblast Transformation and Tumorigenesis.

Authors:  Kathryn N Phoenix; Charan V Devarakonda; Melissa M Fox; Laura E Stevens; Kevin P Claffey
Journal:  Genes Cancer       Date:  2012-01

Review 8.  Dissecting the Dual Role of AMPK in Cancer: From Experimental to Human Studies.

Authors:  Giorgia Zadra; Julie L Batista; Massimo Loda
Journal:  Mol Cancer Res       Date:  2015-05-08       Impact factor: 5.852

9.  Prognostic significance of AMPK activation and therapeutic effects of metformin in hepatocellular carcinoma.

Authors:  Longyi Zheng; Wen Yang; Fuquan Wu; Chao Wang; Lexing Yu; Liang Tang; Bijun Qiu; Yuqiong Li; Linna Guo; Mengchao Wu; Gensheng Feng; Dajin Zou; Hongyang Wang
Journal:  Clin Cancer Res       Date:  2013-08-13       Impact factor: 12.531

10.  Histological evaluation of AMPK signalling in primary breast cancer.

Authors:  Sirwan M Hadad; Lee Baker; Philip R Quinlan; Katherine E Robertson; Susan E Bray; George Thomson; David Kellock; Lee B Jordan; Colin A Purdie; David G Hardie; Stewart Fleming; Alastair M Thompson
Journal:  BMC Cancer       Date:  2009-09-01       Impact factor: 4.430

View more
  5 in total

Review 1.  AMPK and the Challenge of Treating Hypoxic Pulmonary Hypertension.

Authors:  Karen Flores; Patricia Siques; Julio Brito; Silvia M Arribas
Journal:  Int J Mol Sci       Date:  2022-06-01       Impact factor: 6.208

2.  Sequestosome 1 protects esophageal squamous carcinoma cells from apoptosis via stabilizing SKP2 under serum starvation condition.

Authors:  Chao Shi; Bei-Qing Pan; Feng Shi; Zhi-Hui Xie; Yan-Yi Jiang; Li Shang; Yu Zhang; Xin Xu; Yan Cai; Jia-Jie Hao; Ming-Rong Wang
Journal:  Oncogene       Date:  2018-03-19       Impact factor: 9.867

3.  HDAC inhibition as a treatment concept to combat temsirolimus-resistant bladder cancer cells.

Authors:  Eva Juengel; Ramin Najafi; Jochen Rutz; Sebastian Maxeiner; Jasmina Makarevic; Frederik Roos; Igor Tsaur; Axel Haferkamp; Roman A Blaheta
Journal:  Oncotarget       Date:  2017-11-06

4.  Metformin targets a YAP1-TEAD4 complex via AMPKα to regulate CCNE1/2 in bladder cancer cells.

Authors:  Yanju Wu; Qianqian Zheng; Yan Li; Guang Wang; Shuting Gao; Xiaodong Zhang; Xu Yan; Xinwen Zhang; Jisheng Xie; Yuanyuan Wang; Xun Sun; Xin Meng; Bo Yin; Biao Wang
Journal:  J Exp Clin Cancer Res       Date:  2019-08-27

5.  miR-4999-5p Predicts Colorectal Cancer Survival Outcome and Reprograms Glucose Metabolism by Targeting PRKAA2.

Authors:  Qiwei Zhang; Zhi Hong; Jieyao Zhu; Chao Zeng; Zhen Tang; Weiqiang Wang; He Huang
Journal:  Onco Targets Ther       Date:  2020-02-11       Impact factor: 4.147

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.